Dana-Farber Cancer Institute: Fallopian Tube Neoplasms trials

The registry lists 15 Fallopian Tube Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 11No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP InhibitorsRecruitingNCT06710548Not applicable
• A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
• Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
• A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological CancerTerminatedNCT02661815Phase 1Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian CancerTerminatedNCT00910000Phase 1/2Results posted
• Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian MalignanciesCompletedNCT00856180Phase 2Results posted
• Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal CarcinomaCompletedNCT00768144Phase 2Results posted
• Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian TumorsCompletedNCT00520013Phase 2Results posted
• Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian CarcinomaTerminatedNCT00418093Phase 2Results posted
• Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian CancerTerminatedNCT00322881Phase 2Results posted
• SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareWithdrawnNCT04368130Not applicable
• Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2
• Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer PatientsCompletedNCT00268918Phase 1
• Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2